Early treatment of asymptomatic high-risk smoldering myeloma could significantly improve the course of disease, slowing its progression and significantly increasing the survival of patients. This was revealed by a clinical trial conducted by the Spanish Myeloma Group (GEM-Pethema), published in the August issue of the medical journal The New England Journal of Medicine. The authors of the study include Dr. Joan Bladé and Dr. Laura Rosiñol, from the Hematology-Oncology IDIBAPS – Hospital Clínic team.
Archive for the ‘Hospital Clínic’ Category
The hand-held ultrasound could be a useful and effective tool for the screening of abdominal aortic aneurysm in primary care, according to a study led by Dr. Antoni Sisó-Almirall, research director of the Consortium for Primary Health Care of Eixample (CAPSE) and responsible of the IDIBAPS Transversal Group in Primary Care Research. The results of the study, published in the journal Medicina Clínica, confirm that using this technique the correlation for this disease between the family doctor with a specific training and the radiologist was 100 percent.
Chronic liver failure is among the top ten causes of death in adults in many countries and constitutes the most common reason for hospital admission amongst all patients with liver diseases. The shortage of liver donors urges the scientific community to design effective treatments for chronic liver failure to improve quality of life and survival in these patients. The EASL-CLIF (European Association for the Study of the Liver – Chronic Liver Failure) consortium is a multicenter organization, coordinated from IDIBAPS – Hospital Clínic of Barcelona by the team led by Dr. Vicente Arroyo and Dr. Pere Ginés, specifically aimed at promoting research projects on Chronic Liver Failure. Recently this Consortium published an article in Gastroenterology, with Dr. Richard Moreau from Hôpital Beaujon (Paris, France) as its first author, describing acute-on-chronic liver failure as a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
The Clinical and Experimental Respiratory Immunoallergy team receives two presentation awards at the EAACI-WAO Congress
Two members of the IDIBAPS Clinical and Experimental Respiratory Immunoallergy team (IRCE), the predoctoral researcher Francisco de Borja Callejas Díaz and the postdoc Dr. Laura Pujols i Tarrés, have been awarded for their presentations at the 2013 European Academy of Allergology and Clinical Immunology – World Allergy Organization (EAACI-WAO) Congress held in Milan (Italy) from June 22nd-26th. These awards mean recognition for the quality of the scientific work undergone by the team led by Dr. Joaquim Mullol.
A triple therapy increases the sustained virological response in patients co-infected with HIV and hepatitis C virus
About a third of people infected with HIV in the USA and Europe are also infected with hepatitis C virus (HCV). A work published in The Lancet Infectious Diseases suggests a novel combination of drugs, already used successfully in HCV patients, which achieves a better sustained virological response in co-infected patients too. Dr. Josep Mallolas, from the AIDS and Infectious Diseases team at IDIBAPS – Hospital Clínic of Barcelona, is the third author of this work coordinated from the Johns Hopkins University School of Medicine (Baltimore, USA) and funded by Merck.
Spanish Diabetes Society (SED) is a multidisciplinary scientific organization which promotes advances in prevention and treatment of diabetes. Every two years it announces, through its SED Foundation chaired by Dr. Bernat Soria, the Carrasco y Formiguera Junior Clinical Researcher Award, to recognize the work of a clinical researcher under 40 years. This prize was awarded to Dr. Margarita Gimenez Alvarez, from the Endocrinology Service at the Hospital Clinic of Barcelona and collaborator of the IDIBAPS team Diabetes: metabolic and molecular networks, directed by Dr. Josep Vidal. In this interview (in Spanish) for the journal Diabetes, Dr. Giménez explains her passion for research and her patients and talks about the possible future of the disease.